LONDON--(BUSINESS WIRE)--LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced its Bi-Flow Extracorporeal Membrane Oxygenation (ECMO) cannula earned ...
Los Angeles, Calif. - January 15, 2009 - Avalon Laboratories, LLC (Avalon) today announced it has received 510(k) clearances from the U.S. Food and Drug Administration (FDA) and CE Mark acceptance ...
Acquisition Further Strengthens MAQUET's Suite of Products for Extracorporeal Life Support MAQUET Cardiopulmonary, a business unit of MAQUET Cardiovascular and a leader in extracorporeal membrane ...
The current trend of using two cannulas to place most newborns in respiratory failure on life-sustaining ECMO, one in the right internal jugular vein and a second in the right common carotid artery, ...
The global arterial cannula market has witnessed remarkable growth, reaching a market value of USD 21 billion in 2023. With a robust compound annual growth rate (CAGR) of 6.6%, this market is ...
Bi-Flow is first bidirectional femoral arterial cannula validated for 29 days’ use LONDON--(BUSINESS WIRE)-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, ...
Bi-Flow is first bidirectional femoral arterial cannula validated for 29 days' use LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced its Bi-Flow ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback